Table 1

Demographics and risk factors between those anticoagulated early and late

VariableAll (n=1355)Anticoagulated early (n=358)Anticoagulated late or not at all (n=997)
Age, mean (SD)76 (10)75 (11)76 (10)
Sex, female, n (%)580 (43)147 (41)433 (43)
Hypertension, n (%)846 (63)211 (59)635 (65)
Diabetes mellitus, n (%)222 (16)54 (15)168 (17)
Hyperlipidaemia, n (%)597 (45)156 (44)441 (45)
NIHSS, median (IQR)*4 (2–10)2 (1–4)6 (3–11)
Previous stroke/TIA, n (%)277 (21)77 (22)200 (20)
Previous ICH, n (%)13 (1.0)1 (0.28)12 (1.22)
Antiplatelet therapy prior to qualifying stroke, n (%)703 (52)198 (55)505 (51)
Known cognitive impairment or dementia, n (%)32 (3)9 (3)23 (3)
Premorbid mRS, median (IQR)1 (1–3)1 (0–2)2 (1–3)
Dependent living prior to stroke, n (%)144 (12)12 (4)132 (16)
Thrombolysis, n (%)263 (19)43 (12)220 (22)
Bridging heparin, n (%)324 (24)93 (26)231 (23)
CHA2DS2-VASc score, median (IQR)5 (4–6)5 (4–6)5 (4–6)
Qualifying ischaemic stroke >1/3 territory, n (%)242 (18)22 (6)220 (22)
Qualifying ischaemic stroke lacunar, n (%)98 (8)28 (8)70 (8)
PH1 Haemorrhagic transformation, n (%)17 (1.3)0 (0%)17 (1.8)
DOAC on discharge, n (%)475 (37)164 (46)311 (34)
Statin on discharge, n (%)1043 (79)266 (75)777 (81)
Antiplatelet on discharge717 (53)114 (32)603 (60)
Cerebral microbleed presence, n (%)269 (21)74 (21)195 (21)
Moderate to severe WMH, n (%)368 (29)93 (26)275 (30)
  • *Available in 851 of 1080 (79%) of patients with non-minor ischaemic stroke.

  • DOAC, direct oral anticoagulant; ICH, intracranial haemorrhage; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Score; PH1, parenchymal haemorrhage type 1; TIA, transient ischaemic attack; WMH, white matter hyperintensity.